Frank R G
Harvard University, USA.
Health Aff (Millwood). 2001 Mar-Apr;20(2):115-28. doi: 10.1377/hlthaff.20.2.115.
The fact that sick elderly people without prescription drug coverage pay far more for drugs than do people with private health insurance has created a call for state and federal governments to take action. Antitrust cases have been launched, state price control legislation has been enacted, and proposals for expansion of Medicare have been offered in response to price and spending levels for prescription drugs. This paper offers an analysis aimed at understanding pricing patterns of brand-name prescription drugs. I focus on the basic economic forces that enable differential pricing of products to exist and show how features of the prescription drug market promote such phenomena. The analysis directs policy attention toward how purchasing practices can be changed to better represent groups that pay the most and are most disadvantaged.
没有处方药保险的老年病人买药花费比有私人医疗保险的人多得多,这一事实促使人们呼吁州政府和联邦政府采取行动。反垄断案件已经启动,州价格控制立法已经颁布,针对处方药的价格和支出水平,有人提出了扩大医疗保险的提议。本文提供了一项分析,旨在了解品牌处方药的定价模式。我关注使产品差异化定价得以存在的基本经济力量,并展示处方药市场的特征如何促成这种现象。该分析将政策关注点引向如何改变购买方式,以更好地代表支付最多且处境最不利的群体。